Ticker | Company Name | Drug Name | Indication | NCT | Next Catalyst | Stage | FDA Status | Catalyst Date | Conference | Market Cap | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
P PHAR | Pharming Group N.V. | Leniolisib - (pediactric) | Activated phosphoinositide 3-kinase delta syndrome (APDS) | NCT05438407 | PDUFA priority review | 2026-01-31 | $1.3B | $8.1K | |||
A AQST | Aquestive Therapeutics Inc. | Anaphylm (AQ-109)- (103) | Anaphylaxis | Regulatory Decision | PDUFA | Ongoing | 2026-01-31 | $403.8M | $3.3M | ||
R RGNX | REGENXBIO Inc. | clemidsogene lanparvovec (RGX-121) - (CAMPSIITE) | MPS II (Hunter Syndrome) | NCT03566043 | Regulatory Decision | PDUFA | Ongoing | 2026-02-08 | $689.5M | $393.0K | |
V VNDA | Vanda Pharmaceuticals Inc. | Bysanti (milsaperidone) | Acute bipolar I disorder | Regulatory Decision | PDUFA | Ongoing | 2026-02-21 | $441.5M | $531.4K | ||
E ETON | Eton Pharmaceuticals Inc. | ET-600 | Endocrinology condition | Regulatory Decision | PDUFA | Ongoing | 2026-02-25 | $406.0M | $308.3K | ||
X XOMA | XOMA Royalty Corporation | Seralutinib (GB002) - (TORREY/PROSERA) | Pulmonary arterial hypertension (PAH) | NCT05934526 | Topline Data | Phase 3 | Enrollment Conclusion | 2026-02-28 | $326.5M | $51.8K | |
G GOSS | Gossamer Bio Inc. | Seralutinib (GB002) - (TORREY/PROSERA) | Pulmonary arterial hypertension (PAH) | NCT05934526 | Topline Data | Phase 3 | Enrollment Conclusion | 2026-02-28 | $583.3M | $3.0M | |
R RGNX | REGENXBIO Inc. | RGX-314 - (ALTITUDE) | Diabetic retinopathy | NCT04567550 | Submission | NDA Filing | Trial Planned | 2026-02-28 | Link | $689.5M | $393.0K |
C CLSD | Clearside Biomedical Inc. | RGX-314 - (ALTITUDE) | Diabetic retinopathy | NCT04567550 | Submission | NDA Filing | Trial Planned | 2026-02-28 | Link | $2.1M | $11.1K |
A ABBV | AbbVie Inc. | RGX-314 - (ALTITUDE) | Diabetic retinopathy | NCT04567550 | Submission | NDA Filing | Trial Planned | 2026-02-28 | Link | $378.8B | $7.2M |
Rows per page
Page 1 of 37